Why the study?
The development of pulmonary hypertension in heart failure patients increases morbidity and mortality, prompting an examination of recent changes in definitions, diagnosis, and management.
Key points are not available for this paper at this time.
Design
Review article
Answers are grounded in this paper and cite their sources.
Avoids routine PH-specific therapies in left heart disease; confirms trial failures and leaves open refined subgroup research.
The development of pulmonary hypertension (PH) in patients with heart failure is associated with increased morbidity and mortality. In this article, the authors examine recent changes to the definition of PH in the setting of left heart disease (PH-LHD), and discuss its epidemiology, pathophysiology and prognosis. They also explore the complexities of diagnosing PH-LHD and the current evidence for the use of medical therapies, promising clinical trials and the role of left ventricular assist device and transplantation.
No takes yet. Share an insight, caveat, or question.
Rao et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: